Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer

Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2–overexpressing metastatic breast cancer

© 2013 by American Society of Clinical Oncology. Purpose: Lapatinib is an oral small-molecule tyrosine kinase inhibitor of both epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2). This study is designed to test whether the addition of lapatinib to paclitaxel improve...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhongzhen Guan, Binghe Xu, Michelle L. Desilvio, Zhenzhou Shen, Wichit Arpornwirat, Zhongsheng Tong, Vicharn Lorvidhaya, Zefei Jiang, Junlan Yang, Anatoly Makhson, Wai Lim Leung, Mark W. Russo, Beth Newstat, Li Wang, George Chen, Cristina Oliva, Henry Gomez
Format: Journal
Published: 2018
Subjects:
Biochemistry, Genetics and Molecular Biology
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84880452171&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/52240
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84880452171&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/52240

Similar Items